Evidence map›Paper›PMID 33815679›Full record

ArticleWorld journal of hepatology2021

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation.

Khalid Ibrahim Bzeizi, Ali Albenmousa, Abdulhaleem Mohamed Shawkat, Zidan Ahmed, Saleh Alabbad, Waleed Al-hamoudi, Roberto Troisi, Deiter Broering

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Khalid Ibrahim BzeiziDepartment of Liver Transplantation, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia. kbzeizi@kfshrc.edu.sa.
Ali AlbenmousaDepartment of Liver Transplantation, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.
Abdulhaleem Mohamed ShawkatDepartment on Internal medicine, Faculty of Medicine, Minia University, Mina 1234, Egypt.
Zidan AhmedDepartment of Liver and Small Bowel Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.
Saleh AlabbadDepartment of Liver and Small Bowel Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.
Waleed Al-hamoudiDepartment of Liver and Small Bowel Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.
Roberto TroisiDepartment of Liver and Small Bowel Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.
Deiter BroeringOrgan Transplant Center, King Faisal Specialist Hosp and Res Ctr, Riyadh 11211, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOnce daily tacrolimus regimen was found to exhibits similar bioavailability, safety and efficacy properties compared to twice-daily tacrolimus in kidney transplantation patients.

aimTo compare the efficacy and safety of once-daily prolonged release tacrolimus compared to twice-daily tacrolimus in liver transplantation patients.

methodsMEDLINE, EMBASE, CENTRAL databases were searched for clinical trials until December 2020. Efficacy outcome measured as the rate of treatment failure indicated by biopsy-proven acute rejection, Serum creatinine, graft loss, or death. Two reviewers independently selected studies, collected data and assessed risk of bias. The results are reported as risk ratio with 95% confidence interval (CI) for dichotomous data.

resultsSeven studies included with 965 patients. All the included studies were of moderate quality according to the risk of bias assessment using Cochrane Risk of Bias tool. Biopsy-proven acute rejection was reported in four studies, and pooled analysis of those studies indicated similar rejections in both twice daily and once daily tacrolimus groups (risk ratio: 1.06, 95%CI: 0.84-1.34,

conclusionThe analysis findings confirm that both once daily and twice daily tacrolimus formulations are comparable in terms of efficacy and safety outcomes.

Indexed as

FK levelGraft rejectionLiver transplantationProlonged releaseRenal impairmentTacrolimus

Identifiers

PMID33815679
PMCPMC8006077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.